About: Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.31 (+0.94%)
AVIR NASDAQ Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc share price
Atividade de preço de AVIR
Último preço
$ 4,310
Variação (24h)
0,04 USD (0,94%)
Volume
280.57K
Volume (média 4 sem.)
-
Abertura
$ 4,30
Variação do dia
$ 4,26 - $ 4,50
Fechamento anterior
$ 4,27
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
AVIR price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals